The Klein Law Firm announces the commencement of an investigation of Endo International plc (NASDAQ: ENDP) concerning possible violations of federal securities laws. On June 8, 2017, the U.S. Food and Drug Administration (the "FDA") requested Endo pull its opioid painkiller OPANA ER off the U.S. market. According to the FDA, Opana's "high risk of abuse and potential to help spread HIV and hepatitis C" necessitated its removal from the market. If you suffered a loss in Endo International and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ENDP-Info-Request-Form-196. Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.